Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy

处于癌症免疫治疗前沿的新兴细胞疗法

基本信息

批准号：
10540496
负责人：
TERRY L. SHEPPARD
金额：
$ 1.1万
依托单位：
KEYSTONE SYMPOSIA
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-01-29 至 2023-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10540496
关键词：
Achyrocline Address Affect Alberta province Antibodies Area Benign Biodistribution Biological Products Biology Canada Cell Culture Techniques Cell Therapy Cells Cellular biology Cellular immunotherapy Chemistry Collaborations Development Drug Kinetics Educational workshop Effectiveness Engraftment Event Extravasation Functional disorder Future Gene Transfer Genetic Genome engineering Hematologic Neoplasms Immune Immunosuppression Individual Industrialization Intuition Knowledge Learning Malignant - descriptor Malignant Neoplasms Metabolic Methodology Modeling Normal tissue morphology Outcome Research Research Personnel Scientist Solid Neoplasm Speed Technology Therapeutic Therapeutic Index Time Tissues Toxic effect Translations Tumor Biology Work cancer cell cancer immunotherapy cancer therapy career clinical implementation clinical practice differential expression fitness holistic approach improved in vivo insight interest multidisciplinary neoplastic new technology next generation novel novel strategies posters programs resilience small molecule success symposium synthetic biology trafficking translational scientist

项目摘要

ABSTRACT Support is requested for a Keystone Symposia conference entitled Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy, organized by Drs. Francesco Marincola, Lisa Butterfield, David Stroncek and Marcela Maus. The conference will be held in Banff, Alberta, Canada from January 29-February 2, 2023. Cellular immunotherapy for the treatment of hematological malignancies and solid tumors is rapidly progressing. Progress depends upon the development of better products that match the challenges limiting effectiveness such as survival and engraftment, trafficking to cancer tissues, engagement with cancer cells, and resilience to immune-suppressive factors while at the same time de-risking toxicity. This can be only achieved following a holistic approach to achieve an optimal therapeutic index. Such estimation goes beyond the selection of antigenic targets based of differential expression between benign and neoplastic tissues as is intuitively done for small molecules, antibodies and other biologics where the engagement of the product with its target is dependent on stable chemistry and predicable pharmacokinetics. Cell therapies instead are affected by active rather than passive biodistribution, and context dependent potency. Thus, a broader range of factors need to be considered like product-dependent variability (fitness, unpredictable pharmacokinetics due non-specific trapping, sequestration and extravasation into normal tissues, and variable rates of in vivo expansion). Individual cancer immune biology may affect differential trafficking to benign compared to malignant tissues under different conditions of chemo-attraction, hampered engagement with cancer cells due to physical or functional barriers, immune suppression, and cellular dysfunction due to unfavorable metabolic conditions. This conference gathers expertise from all areas, to propose an integrated path forward to successful implementation of novel cellular therapeutics, particularly for solid tumors.

抽象的请求支持题为“新兴细胞疗法”的 Keystone 研讨会癌症免疫疗法的前沿，由博士组织。弗朗西斯科·马里科拉、丽莎·巴特菲尔德、大卫·斯特龙塞克和马塞拉·莫斯。会议将于2023年1月29日至2月2日在加拿大艾伯塔省班夫举行。细胞免疫疗法治疗血液恶性肿瘤和实体瘤正在迅速发展进步。进步取决于开发更好的产品来应对限制的挑战有效性，例如存活和植入、运输至癌症组织、与癌细胞的接触，和对免疫抑制因素的抵抗力，同时降低毒性风险。这只能是通过整体方法实现最佳治疗指数。这样的估计超出了根据良性组织和肿瘤组织之间的差异表达选择抗原靶标直观地针对小分子、抗体和其他生物制剂进行，其中产品与其目标取决于稳定的化学性质和可预测的药代动力学。相反，细胞疗法是受主动而非被动生物分布和环境依赖性效力的影响。因此，范围更广需要考虑多种因素，例如产品依赖性变异性（适应性、不可预测的药代动力学）由于非特异性捕获、隔离和外渗到正常组织中，以及体内的可变速率扩张）。与良性相比，个体癌症免疫生物学可能会影响良性运输的差异恶性组织在不同的化学吸引条件下，由于与癌细胞的接触而受到阻碍由于不利的代谢导致的身体或功能障碍、免疫抑制和细胞功能障碍状况。本次会议汇集了各领域的专业知识，提出了一条综合的前进道路成功实施新型细胞疗法，特别是针对实体瘤。